Recruiting Clinical Trials

Displaying 81 - 90 of 245 result(s)
Study Title Condition Phase Location
Phase II/III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth Prostatic Neoplasms, Prostate Cancer Phase 2, Phase 3
  • Country: 
    France
  • Country: 
    Italy
  • Country: 
    Spain
  • Country: 
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population Lupus Nephritis Not Given
  • Country: 
    Taiwan
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China Psoriasis Not Given
  • Country: 
    China
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-a ... Chronic Spontaneous Urticaria Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis) Secondary Progressive Multiple Sclerosis (SPMS) Not Given
  • Country: 
    Japan
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Germany
  • Country: 
A 24-week Prospective, Open-label, Multicenter, Single-arm Regulatory Post-Marketing Surveillance (rPMS) Study in Real-world Setting (Mandatory by Local HA Regulation) for Atectura® (QMF149 150/80 μg o.d., QMF149 150/160 μg o.d. and QMF149 150/320 μg ... Asthma Not Given
  • Country: 
    Korea, Republic of
A Phase II Study to Evaluate the Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) PIK3CA-related Overgrowth Spectrum (PROS) Phase 2
  • Country: 
    United States
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Partic ... Breast Cancer Phase 2
  • Country: 
    United States
  • Country: 
    Hong Kong
  • Country: 
    Malaysia
  • Country: 
A Phase II Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Chinese Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, PIK3CA Mutant Advanced Breast Cancer Which Progressed on ... Breast Neoplasms Phase 2
  • Country: 
    China